Is big pharma really on cusp of AI shake-out?

Pharma IQ
Posted: 07/14/2017

Artificial intelligence could herald a new era for drug development but caution remains about how revolutionary its impact will actually be  GlaxoSmithKline’s $43m deal with British AI firm Exscientia may signal a revolution for drug development that could radically speed up the drug discovery process, helping patients in urgent need of

To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

Pharma IQ
Posted: 07/14/2017

Pharma IQ Members

EVENTS OF INTEREST

London, UK
November 27 - 28, 2017
Vienna Marriott Hotel, Vienna, Austria
November 26 - 28, 2017
Hilton Brussels Grand Place, Brussels, Belgium
November 27 - 29, 2017